Analyst Rating Update on Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX) : The consensus on Quest Diagnostics Incorporated (DGX) based on 16 analyst recommendation on the company stock is 3.02, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 13 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Quest Diagnostics Incorporated (DGX).

Quest Diagnostics Incorporated (DGX) : The most positive equity analysts on Quest Diagnostics Incorporated (DGX) expects the shares to touch $90, whereas, the least positive believes that the stock will trade at $70 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $79.25 with an expected fluctuation of $6 from the mean.

Company shares have received an average consensus rating of Hold for the current week


Quest Diagnostics Incorporated (NYSE:DGX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $85.38 and $85.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $85.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $85.65, notching a gain of 0.48% for the day. The total traded volume was 865,624 . The stock had closed at $85.24 on the previous day.

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.